Literature DB >> 2164445

3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.

N Horichi1, H Tapiero, Y Sugimoto, M Bungo, M Nishiyama, A Fourcade, T J Lampidis, K Kasahara, Y Sasaki, T Takahashi.   

Abstract

The mechanism of action of 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) was examined in a human leukemia cell line (K562) and its Adriamycin (ADM)-resistant subline (K562/ADM). ADM and MX2 showed an equivalent antitumor effect against K562. K562/ADM was highly resistant to ADM. In cellular pharmacokinetic studies, MX2 showed faster and greater influx than did ADM in both K562 and K562/ADM. The efflux of ADM was rapid in K562/ADM but not in K562. On the other hand, the efflux of MX2 was rapid in both cell lines. The formation of DNA single-strand breaks and double-strand breaks by ADM was significantly lower in K562/ADM than K562. On the other hand, formation of those breaks by MX2 was not decreased. Although some of the DNA breaks induced by MX2 were resealed, there was no difference in the degree of resealing in K562 and K562/ADM cells. On the other hand, most of the small number of DNA breaks in K562/ADM induced by ADM were resealed. The topoisomerase II activity in K562 and K562/ADM was not significantly different. It is concluded that MX2 conquers multidrug resistance by rapid influx following a higher frequency of formation of DNA single- and double-strand breaks in K562/ADM cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164445

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.

Authors:  J Kuratsu; N Arita; K Kurisu; T Uozumi; T Hayakawa; Y Ushio
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

2.  Intrathecal chemotherapy with MX2 for treating glioma dissemination in vivo.

Authors:  S Mizumatsu; K Matsumoto; Y Ono; T Tamiya; T Furuta; T Ohmoto
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

3.  Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.

Authors:  R Perez-Soler; Y H Ling; Y Zou; W Priebe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Characterization of an etoposide-resistant human ovarian cancer cell line.

Authors:  N Kubota; K Nishio; Y Takeda; T Ohmori; Y Funayama; H Ogasawara; T Ohira; H Kunikane; Y Terashima; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.

Authors:  A A Ebrahim el-Zayat; M A Izquierdo; G M Clark; D D Von Hoff
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

6.  Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles.

Authors:  Y Zou; W Priebe; Y H Ling; R Perez-Soler
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.

Authors:  F Kanzawa; K Nishio; T Ishida; M Fukuda; H Kurokawa; H Fukumoto; Y Nomoto; K Fukuoka; K Bojanowski; N Saijo
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Characterisation of a vindesine-resistant human small-cell lung cancer cell line.

Authors:  S Ohta; K Nishio; S Kubo; M Nishio; T Ohmori; T Takahashi; N Saijo
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

9.  Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.

Authors:  X F Hu; A Slater; D Rischin; P Kantharidis; J D Parkin; J Zalcberg
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

10.  Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker.

Authors:  D H Lau; G E Duran; A D Lewis; B I Sikic
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.